EIT Health, alongside its partners Takeda and KU Leuven, is seeking solutions that turbocharge the most promising technologies for monitoring inflammatory bowel disease (IBD). We are looking for solutions that aim to solve the following challenges:
a) Early detection of flares in inflammatory bowel disease – Solutions that can improve the early detection of flares. Such as regular monitoring of symptoms, detecting patterns of bowel movements, diarrhoea, rectal bleeding, weight loss or fatigue.
b) New biomarkers for inflammatory bowel disease – Solutions that provide new biomarkers are emerging, such as microbial, genetic, proteomic, exosome-derived or new body fluids biomarkers. Also, new digital biomarkers that include measurable, quantifiable data collected through digital means (such as mobile apps, sensors, wearables or other devices) can provide insights into the disease’s progression, severity or response to treatment.
c) Understanding IBD behaviour better (optional: can be combined with a & b) – Solutions that connect and review patient’s medical history, including past flare patterns, hospitalisations and medication adjustments, can assist in identifying early signs of recurrent flares. Keeping track of lifestyle changes, dietary habits, stress levels, and triggers that might exacerbate symptoms can aid in recognising early warning signs of a flare.
The desired impact of a solution that allows for fast, regular and minimal invasive remote monitoring of people with Inflammatory Bowel Disease (IBD) is to: